~$1.45 billion acquisition expected to expand Vertiv's addressable opportunity in power-constrained data centers

UIG's proven team and proprietary technology add microgrid controls, onsite generation orchestration, microgrid-specific switchgear and behind-the-meter power architecture to Vertiv's portfolio

Extends Vertiv's power and cooling portfolio from grid interconnect to chip, independent of any single generation technology or supplier

COLUMBUS, Ohio, Oct. 27, 2026 /PRNewswire/ -- Vertiv Holdings Co. (NYSE: VRT) ("Vertiv"), a global leader in critical digital infrastructure, today announced its wholly-owned subsidiary, Vertiv Corporation, has completed its acquisition of Utility Innovation Holdings, Inc., which operates as UtilityInnovation Group ("UIG") for approximately $1.45 billion in upfront cash. The transaction includes additional contingent consideration of up to $1.15 billion in cash based on achieving certain earnings before interest, taxes, depreciation and amortization ("EBITDA") targets over 12- and 24-month periods.

At the approximately $1.45 billion purchase price, the acquisition represents approximately 13x expected UIG 2027 EBITDA. The EBITDA multiple is anticipated to be significantly lower if the full earnout is paid. Vertiv expects the acquisition to be accretive to adjusted earnings per share in the first year following completion.

UIG is a leader in microgrid solutions, advanced power controls and behind-the-meter power architecture design for data centers. The acquisition extends Vertiv upstream to the grid interconnect, adding microgrid controls, onsite generation and energy storage orchestration, and behind-the-meter power architecture. These capabilities are expected to help data center operators secure power faster as grid constraints increasingly limit AI infrastructure deployment.

"We are pleased to welcome the UIG team to Vertiv," said Vertiv CEO Giordano Albertazzi. "As AI data center operators work to accelerate deployment in an increasingly power-constrained environment, access to power has become a critical competitive advantage. With UIG now part of Vertiv, we can extend our capabilities upstream to the utility interconnect and onsite power sources, creating a coordinated solution, from behind-the-meter power generation to chip, that helps customers achieve faster time to power without tying them to a single generation technology or supplier."

The Vertiv and UIG combination is expected to give customers greater flexibility in how they source, manage and scale power as data center requirements evolve by:

- Accelerating access to power to ease or eliminate dependence on utility interconnection timelines,

- Enabling Behind the Meter (BTM) site capacity to scale beyond what the grid alone can provide, and

- Providing a single accountable relationship from grid interconnect through rack-level infrastructure.

"UIG is excited to advance its mission to solve the power constraints that are slowing AI data center development," said Sidney Hinton, Founder and CEO of UIG. "As part of Vertiv, we will be able to bring our microgrid and behind-the-meter power expertise to a broader set of customers globally, helping accelerate deployment of the critical infrastructure needed to support the growth of AI."

J.P. Morgan Securities LLC acted as financial advisor to Vertiv, and Buchanan Ingersoll & Rooney PC served as legal counsel. Morgan Stanley & Co. LLC acted as financial advisor to UIG, and Davis Polk & Wardwell LLP served as legal counsel.

For more information about Vertiv's end-to-end portfolio of power and thermal management systems, infrastructure solutions and lifecycle services, visit Vertiv.com.

About Vertiv Holdings Co.

Vertiv Holdings Co. (NYSE: VRT) brings together hardware, software, analytics and ongoing services to enable its customers' vital applications to run continuously, perform optimally and grow with their business needs. Vertiv solves the most important challenges facing today's data centers, communication networks and commercial and industrial facilities with a portfolio of power, cooling and IT infrastructure solutions and services that extends from the cloud to the edge of the network. Headquartered in Westerville, Ohio, USA, Vertiv does business in more than 130 countries. For more information, and for the latest news and content from Vertiv, visit Vertiv.com.

Category: Financial News

About UIG

Founded in 2020, UIG is headquartered in Raleigh, North Carolina, with European headquarters in Dublin, Ireland, and manufacturing operations in North Carolina and New Jersey. The company designs and delivers power systems that support real-time load and frequency balancing across behind-the-meter systems and utility-connected energy resources, helping address the power demands of AI data center workloads. Its solutions include proprietary controls software, customized microgrid switchgear and energy storage.

Forward-looking statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27 of the Securities Act, and Section 21E of the Securities Exchange Act. These statements are only a prediction. Actual events or results may differ materially from those in the forward-looking statements set forth herein. Readers are referred to Vertiv's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q for a discussion of these and other important risk factors concerning Vertiv and its operations. Those risk factors and risks related to the transaction, among others, could cause actual results to differ materially from historical performance and include, but are not limited to: the successful integration of UIG; expected expenses related to the integration; the possible diversion of management time on issues related to the integration; the ability of Vertiv to maintain relationships with customers and suppliers of UIG; the ability of Vertiv to retain management and key employees of UIG; and whether Vertiv would realize anticipated synergies and accretion contemplated by the acquisition. Vertiv is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

For investor inquiries, please contact:

Lynne Maxeiner

Vice President, Global Treasury & Investor Relations

Vertiv

E: [email protected] 

For media inquiries, please contact:

Ruder Finn for Vertiv

E: [email protected] 

SOURCE Vertiv Holdings Co

Share this article

Versatile tabletop system enables students to explore how various materials behave under load as they design and run their own experiments

BEAVERTON, Ore., Oct. 27, 2026 /PRNewswire/ -- Vernier Science Education recently launched the Go Direct® Materials Test Frame to support hands-on data collection and analysis in teaching laboratories. The versatile tabletop system helps college students explore various biomechanics and engineering concepts as they investigate how a wide range of materials respond to applied loads and use real-time data to characterize their mechanical properties.

"This affordable Vernier test frame is comparable to higher-priced models and intuitive enough for multiple student groups to be up and running quickly. Students gain authentic experience designing experiments, collecting data, and analyzing material behavior across disciplinesâbiomedical engineering, mechanical engineering, materials science, and more," said Jenni Buckley, PhD, associate dean and professor of mechanical engineering at the University of Delaware. Vernier partnered with Dr. Buckley and her department on the development of the Go Direct Materials Test Frame.

The Go Direct Materials Test Frame supports multiple-station setups, allowing students to conduct experiments and collect data themselves. Using the award-winning Vernier Graphical Analysis® app on mobile devices, Chromebooksâ¢, or computers, students can analyze their data and explore a wide range of applications, including:

- Characterizing the mechanical behavior of biological tissues and investigating the strength of medical devices

- Comparing the strength of plastics, metals, and composites, as well as student-designed or 3D-printed materials

- Examining stress-strain behavior to characterize material stiffness and failure

- Exploring the transition between elastic and plastic deformation

The Go Direct Materials Test Frame enables students to collect real-time force measurements up to ±4,000 N and displacement data across a range of approximately 0â23 cm. It provides high-resolution measurements of 0.18 N for force and 0.51 μm for displacement. Adaptable features also accommodate test specimens more than 60 cm in length, giving students the flexibility to investigate a wide range of materials.

Educators can access a free, open-source biomechanics curriculum developed by the University of Delaware, featuring clinically relevant engineering mechanics, materials, and design investigations using the Vernier Go Direct Materials Test Frame. The lab-ready, field-tested investigations cover topics such as musculoskeletal tissue mechanics, orthopaedic fracture plate design, clinical case studies, human movement analysis, applications of engineering mechanics, and experimental design.

"Whether they're investigating biological tissues, medical devices, or materials they've designed themselves, students can now more easily explore how materials behave in the real world," said Jill Hedrick, CEO of Vernier Science Education. "This kind of student-driven, hands-on exploration engages them in the discovery process and makes biomechanical and engineering concepts more tangible."

The Go Direct Materials Test Frame is available at a limited-time introductory price of $3,495. It is backed by Vernier's product support and five-year limited warranty.

To learn more about the Go Direct Materials Test Frame, visit

https://www.vernier.com/go-direct-materials-test-frame/.

About Vernier Science Education

For more than 45 years, Vernier Science Education has been committed to using our experience, knowledge, and passion to create the best and most reliable solutions for STEM education. Our comprehensive solutions include hardware, software, content, assessment, professional development, and technical support. At the heart of Vernier is our deep commitment to being an authentic and trusted partner to STEM educators. We are dedicated to partnering with educators and communities to build a STEM-literate society where students grow up to become knowledgeable citizens who can solve problems, fully contribute to their communities, and drive innovation. For more information, visit www.vernier.com.

SOURCE Vernier Science Education

Share this article

-- Global Phase 1/2 trial will evaluate ATR 1072 in approximately 37 participants --

-- Initial proof of concept data expected in second half of 2027 --

SAN DIEGO, Oct. 27, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that the first patient has been dosed in the Phase 1/2 Corventis clinical trial evaluating ATR 1072, its lead investigational therapy for the potential treatment of PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome. The Company expects to report initial proof-of-concept data from Corventis in the second half of 2027.

"Dosing the first patient in the Corventis clinical trial is a milestone for Atrium and, more importantly, for the PRKAG2 community. This is the first clinical trial for people living with PRKAG2 syndrome evaluating a potential treatment for the underlying cause of the disease. It is also an important step for the broader genetic cardiomyopathy field as it moves toward treating these diseases at their root cause," said Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics. "This achievement reflects the dedication of our team and was made possible by our strong partnerships with our clinical trial sites and the support of the PRKAG2 syndrome patient community."

"Today, the best we can offer people with PRKAG2 syndrome is a pacemaker, a defibrillator, and our best efforts to prevent life-threatening arrhythmias â we manage the consequences of the disease, not the disease itself. Dosing the first patient with an investigational therapy designed to go after the genetic root cause is a real step forward for families affected by this rare genetic cardiomyopathy," said Michael Nassif, M.D., a heart failure cardiologist at Saint Luke's Mid America Heart Institute.

PRKAG2 syndrome is a severe, life-threatening, rare autosomal dominant progressive cardiomyopathy with no approved therapies. It is caused by genetic mutations in PRKAG2 that lead to overactivity of AMP-activated protein kinase (AMPK), resulting in glycogen accumulation in heart muscle, which may lead to heart failure and sudden cardiac death. ATR 1072, based on the Company's targeted RNA delivery platform, is an antibody oligonucleotide conjugate (AOC) designed to silence mutant PRKAG2 messenger RNA (mRNA) to normalize AMPK overactivation and improve heart function.

About ATR 1072

ATR 1072, the Company's lead product candidate, is a potentially disease-modifying treatment for PRKAG2 syndrome. Using Atrium's precision RNA delivery technology, ATR 1072 uses small interfering RNA (siRNA) to silence mutant PRKAG2 messenger RNA (mRNA), normalize AMP-activated protein kinase (AMPK) activity and reduce pathogenic glycogen accumulation, potentially leading to improved heart function.

About PRKAG2 Syndrome

PRKAG2 syndrome is a rare, autosomal dominant, early-onset cardiomyopathy caused by mutations in the PRKAG2 gene, which encodes the Gamma 2 regulatory subunit of AMPK. Mutations enhance AMPK activity leading to abnormal glycogen accumulation in the heart, thickened heart muscles, electrical conduction problems, and arrhythmias. Based on current scientific literature estimates, there are at least 1,000 â 2,000 people with PRKAG2 syndrome in the US. Current management is limited to symptomatic treatment; no approved therapies exist to address the underlying genetic driver of disease.

About the Corventis⢠Trial

Corventis⢠is a Phase 1/2 open-label, multicenter clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ATR 1072 in participants living with PRKAG2 syndrome. The study will enroll approximately 37 participants across two parts: Part A, multiple ascending dose cohorts to characterize safety and support dose selection, and Part B, a single-arm expansion cohort at the recommended Phase 2 dose to further evaluate efficacy trends in cardiac structure and function. The study's primary endpoint is incidence of treatment-emergent adverse events, with secondary and exploratory endpoints such as PRKAG2 mRNA reduction, siRNA tissue concentrations and plasma pharmacokinetics.

Additional information about the trial is available at www.corventistrial.com.

About Atrium Therapeutics

Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The Company's proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides and is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from demonstrated delivery to skeletal muscle and applies it for efficient delivery to the heart, with the potential to overcome challenges associated with non-specific tissue delivery. The Company's pipeline includes ATR 1072 for PRKAG2 syndrome, ATR 1086 for PLN (phospholamban) cardiomyopathy and two undisclosed research targets in rare cardiomyopathies.

For more information about our RNA delivery platform, development pipeline and people, please visit https://atriumtherapeutics.com/ and engage with us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," " designed to, " " target, " or similar terms, or by express or implied discussions regarding Atrium Therapeutics' ("Atrium's" or "our") product candidates, clinical trials and future results of operations and financial condition. Specifically, this press release contains forward-looking information relating to the design, conduct, enrollment and anticipated progress of the Corventis Phase 1/2 clinical trial, including the expected number of participants; the anticipated timing of initial proof-of-concept data from Corventis; the therapeutic potential of ATR 1072, including its potential to address the underlying genetic cause of PRKAG2 syndrome, to be disease-modifying and to improve heart function; the potential of our targeted RNA delivery platform, including its potential to deliver siRNA to the heart and to overcome challenges associated with non-specific tissue delivery; our estimates of the prevalence of PRKAG2 syndrome; the potential implications of Corventis for the treatment of genetic cardiomyopathies; and the advancement of our pipeline, including ATR 1086 and our research programs. Such forward-looking statements are based on management's current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties.

NEREUS⢠significantly reduced semaglutide induced vomiting including frequent multi-day and extreme vomiting

Key Results

- Any vomiting (primary) 43.0% (61/142) vs 58.5% (96/164) placebo (p=0.006); 27% relative reduction

- Vomiting + severe nausea (key secondary): 33.1% (47/142) vs 50.6% (83/164) (p=0.002); 35% relative reduction

- Frequent multi-day vomiting (>2 episodes on more than one day): 6.3% (9/142) vs 15.9% (26/164) (p=0.008); 60% relative reduction

- Extreme vomiting (>10 total episodes): 2.8% (4/142) vs 14.6% (24/164) (p=0.0003); 81% relative reduction

WASHINGTON, Oct. 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced positive results from Study 3601 (VP-VLY-686-3601), a Phase III randomized, placebo-controlled study evaluating NEREUS⢠(tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting associated with GLP-1 receptor agonist therapy. The study showed significant reduction in overall vomiting episodes (27% p=0.006 as well as reduction of frequent (60% p=0.008) and extreme vomiting (81% p=0.0003) episodes.

Based on the totality of data from the Phase II and Phase III programs, Vanda intends to discuss the results with the U.S. Food and Drug Administration (FDA) and is planning a supplemental New Drug Application (sNDA) to support the use of NEREUS⢠for the prevention of vomiting associated with GLP-1 receptor agonist therapy.

Primary Endpoint (any vomiting)

NEREUS⢠reduced the incidence of any vomiting. Vomiting occurred in 43.0% of NEREUSâ¢-treated participants (61/142) compared with 58.5% on placebo (96/164) (p=0.006, adjusted for site), a 27% relative reduction.

Key Secondary Endpoint (severe nausea and vomiting)

The key secondary endpoint of any vomiting together with worst nausea â¥3 occurred in 33.1% of participants on NEREUS⢠(47/142) versus 50.6% on placebo (83/164) (p=0.002, adjusted for site), a 35% relative reduction.

Higher-Burden Vomiting

Exploratory analyses examined higher-intensity vomiting patterns. The proportion of participants with frequent vomitingâdefined as more than 2 episodes on more than one dayâwas 6.3% with NEREUS⢠versus 15.9% with placebo (p=0.008, site-adjusted), a 60% relative reduction. The proportion with extreme vomiting (greater than 10 total episodes) was 2.8% with NEREUS⢠versus 14.6% with placebo (p=0.0003, site-adjusted), corresponding to an 81% relative reduction. These analyses are post hoc and are presented as supportive evidence of a reduction in higher-burden vomiting. A similar approximately 80% relative reduction in extreme vomiting was observed in the Phase II study.

Time Course

Almost all vomiting episodes in either group occurred by Day 2. Vomiting rates peaked on Day 1, and the absolute separation between NEREUS⢠and placebo was greatest on Days 1 and 2. After Day 2, few additional participants began vomiting. These observations indicate that early preventionâdosing prior to initiation or dose escalation and in the first days after dosing of the GLP-1 analogâis the most impactful window for reducing vomiting.

Study Design and Dosing

The Phase III study tested NEREUS⢠under conditions that produce a high rate of vomiting. Participants received a single 1 mg dose of semaglutide without the gradual titration used in clinical practice. This design provides a rigorous test of prevention when the emetogenic stimulus is strong. A pooled exposureâresponse analysis of the Phase 2 and Phase 3 data showed that the reduction in vomiting probability with NEREUS⢠remained stable across the observed semaglutide concentration range, with no evidence that the treatment effect diminished at lower exposures, supporting extrapolation of the effect to real-world dosing of semaglutide.

Mechanism of Action

NEREUS⢠is an NK-1 receptor antagonist that acts at the vomiting center, including the area postrema (AP) and nucleus tractus solitarius (NTS). By blocking substance P signaling in these central pathways, NEREUS⢠is expected to be applicable across all available GLP-1 receptor agonist therapies.

The Problem and Market Context

Nausea and vomiting are among the most common reasons patients discontinue or fail to reach therapeutic doses of GLP-1 receptor agonists.1,2,3,4 Real-world studies show that roughly half of patients discontinue GLP-1 therapy within one year, with gastrointestinal side effects among the leading reasons.1 The global GLP-1 receptor agonist market exceeds $50 billion and continues to expand.5 Improving tolerability could enable more patients to initiate and remain on therapy.

Next Steps

Vanda plans to discuss the results with the FDA and intends to submit an sNDA for NEREUS⢠for the prevention of vomiting associated with GLP-1 receptor agonist therapy.

Safety

NEREUS⢠was generally well tolerated, with a safety profile consistent with previous studies. No new safety signals were observed.

"These results demonstrate that NEREUS can meaningfully reduce vomiting and frequent multi-day vomiting induced by GLP-1 therapy, which are key contributors to treatment discontinuation," said Dr. Mihael H. Polymeropoulos, President, CEO and Chairman of the Board of Vanda. "The consistency and magnitude of the effects observed across this program could offer significant benefit to the millions of people seeking or using GLP1 therapies."

About NEREUSâ¢

NEREUS⢠(tradipitant) is an oral NK-1 receptor antagonist approved in December of 2025 for the prevention of motion-induced vomiting.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

References

- Mailhac A, Pedersen L, Petersen I, Pottegård A, Sørensen HT, Thomsen RW. Discontinuation of Semaglutide Therapy for Obesity Management. JAMA Netw Open. 2026;9(8):e2631371. doi:10.1001/jamanetworkopen.2026.31371

- Gasoyan H, Butsch WS, Casacchia NJ, Schulte R, Criswell V, Fox J, Renner H, Le P, Alpert J, Rothberg MB. Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice. Obesity (Silver Spring). 2025;33(12):2296-2303. doi:10.1002/oby.70058

- DiStefano MJ, Zon J, Olson EG, Levy JF, Anderson GF, Alexander GC. Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey. J Manag Care Spec Pharm. 2026;32(8):903-910. doi:10.18553/jmcp.2026.32.8.903

- Sørensen MS, Pottegård A, Andersen NE, Thomsen RW, Lundby C. Survey among adult users of semaglutide for weight loss in Denmark: user characteristics, treatment expectations and experienced effects. Diabetes Obes Metab. 2025;27(4):2214-2222. doi:10.1111/dom.16222

- Morgan Stanley Research. Obesity Drugs Are Scaling Fast. April 22, 2026. https://www.morganstanley.com/insights/articles/glp1-weight-loss-market-may-double-190-billion-2035

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this press release, including but not limited to statements regarding the therapeutic potential of NEREUSâ¢; the estimates of patient discontinuation rates and the size and projected growth of the GLP-1 receptor agonist market; the possibility that NEREUS⢠could improve patient adherence and broaden utilization of GLP-1 therapies; Vanda's plans and expectations regarding the regulatory path for NEREUS⢠for the treatment of GLP-1-induced nausea and vomiting; and Vanda's commercial plans for NEREUS⢠for this indication are "forward-looking statements" under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, the ability of NEREUS⢠to mitigate nausea and vomiting in patients being treated with GLP-1 therapies across all available GLP-1 receptor agonist therapies; the accuracy of the estimates of patient discontinuation rates and the size and growth of the GLP-1 receptor agonist market; the ability of NEREUS⢠to improve patient adherence and drive broader utilization of GLP-1 therapies; the sufficiency of the clinical trial data to support the filing of an sNDA for NEREUS⢠for this indication; the FDA's willingness to meet with Vanda to discuss and provide feedback on Vanda's proposed sNDA submission during 2027; Vanda's ability to gain alignment with the FDA on the regulatory path for NEREUS⢠and to obtain FDA approval of NEREUS⢠for the treatment of GLP-1-induced nausea and vomiting; Vanda's ability to use the currently approved NEREUS⢠product for this indication, if approved; and the ability of Vanda's existing commercial infrastructure to support the commercialization of NEREUS⢠for this indication. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda's business and market, particularly those identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's most recent Annual Report on Form 10-K, as updated by Vanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

Shuja Rabbani Advances the Case for HR Leadership in the AI Era at Dubai Summit

HR leaders must build the capability to guide artificial intelligence adoption while remaining accountable for its impact on people. That message shaped Shuja Rabbani's presentation, "From HR Expert to AI Champion: A Roadmap," at the HRSE in Dubai.

DUBAI, UAE, Oct. 27, 2026 /PRNewswire/ -- Presented on 14 October at Dubai World Trade Centre, the session connected practical AI skills with the leadership judgment required to manage workplace transformation. Rabbani explored AI-supported employee performance feedback, structured prompting techniques and the importance of emotional intelligence as technology changes how organizations work.

His presentation also addressed AI ethics and governance, emphasising that responsibility for workplace decisions remains with people. Through his speaking and coaching work, he advocates a stronger strategic role for HR: helping leaders build workforce capability, sustain trust through change and adopt AI responsibly.

Rabbani brings an extensive portfolio of international qualifications to the discussion. He holds SHRM-SCP and SPHRi credentials and is a certified executive coach, trainer and speaker through the John C. Maxwell Leadership organization.

A University of California, Berkeley executive education alumnus, he completed the Berkeley Transformative Chief Human Resources Officer Leadership Program. His professional certifications span EQi 2.0, leadership development, executive coaching and assessment, including qualifications in Hogan Assessments, MBTI, DiSC and Saville Assessments, supporting his work in understanding leadership behaviour and developing enterprise-level organizational capability.

This diverse combination of HR credentials, executive education and psychometric assessment expertise informs his approach to developing leaders and preparing organizations for change. Having presented this workshop to over 300 HR professionals and industry leaders, Rabbani's workshops bring perspective on HR's growing role in enterprise transformation and building a workforce pipeline equipped with skills required for the future.

"Organizations need HR leaders who can help people adapt to AI, build trust during change, strengthen leadership capability, and prepare the workforce for disruption before disruption arrives," said Rabbani.

Drawing on experience across aviation, banking, NGO and government-related sectors, Rabbani positioned AI proficiency as a practical leadership responsibility for HR professionals seeking greater strategic influence.

Shuja Rabbani is a GCC-based speaker, trainer, and executive leadership development coach certified by the John C. Maxwell Leadership organization.

Press Release Service provided by 24-7PressRelease.com.

SOURCE Shuja Rabbani

Share this article

DELRAY BEACH, Fla., Oct. 27, 2026 /PRNewswire/ -- According to MarketsandMarketsâ¢, the global Switchgear Monitoring System Market size is projected to grow from USD 2.36 billion in 2026 to USD 3.80 billion by 2031 at a compound annual growth rate (CAGR) of 10.1% during the forecast period.

Browse over 150 market data tables and 60 figures spread through 310 pages and an in-depth TOC on 'Switchgear Monitoring System Market â Global Forecast to 2031.'

The global market for switchgear monitoring systems is witnessing robust growth driven by several key factors. The expansion and modernization of power transmission and distribution infrastructure are crucial components facilitating this trend. Additionally, the increasing need to improve grid reliability, prevent equipment failures, and comply with stringent electrical safety requirements is further propelling the adoption of these systems. As a result, demand is increasing in line with the industry's shift toward digitalized and condition-based asset management. Switchgear monitoring systems are increasingly deployed for real-time condition monitoring, thermal monitoring, partial discharge detection, fault detection, and predictive maintenance across utility substations, industrial facilities, commercial buildings, renewable energy installations, and data centers. Demand is also supported by the replacement of aging switchgear, expansion of smart grid and digital substation infrastructure, and increasing adoption of IoT-enabled and remotely monitored electrical equipment. North America, Europe, and Asia Pacific remain important markets, supported by extensive power infrastructure and ongoing grid modernization, while rapid electrification, renewable energy development, and industrialization projects in Asia Pacific, the Middle East, and other emerging markets are creating additional opportunities for market growth.

Switchgear Monitoring System Market Size & Forecast:

- Market Size Available for Years: 2022â2031

- 2025 Market Size: USD 2.17 Billion

- 2031 Projected Market Size: USD 3.80 Billion

- CAGR (2026â2031): 10.1%

Switchgear Monitoring System Market Trends & Insights:

- Asia Pacific is expected to register the highest CAGR of 10.6% in the Switchgear Monitoring System Market during the forecast period.

- Gas-insulated switchgear held the largest market share of 67.9%, by switchgear type, in 2025.

- By component, the software segment is expected to register the highest CAGR of 8.8% during the forecast period.

- By voltage, the low voltage segment is expected to register the fastest growth during the forecast period.

- By end user, the utilities segment is likely to hold the largest market share in 2031.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=69776366

By type, the gas-insulated switchgear segment is expected to record a faster growth rate in the Switchgear Monitoring System Market during the forecast period.

Growth is supported by the increasing deployment of compact high-voltage substations, urban power infrastructure, renewable energy projects, and space-constrained transmission and distribution facilities. Gas-insulated switchgear (GIS) installations provide operators with opportunities to integrate advanced monitoring technologies from the initial design stage, including gas-density monitoring, partial discharge detection, temperature monitoring, fault detection, and remote diagnostics. The air-insulated switchgear (AIS) segment, however, remains significant due to its extensive installed base across utility substations, industrial facilities, commercial buildings, and distribution networks. Monitoring systems for AIS enable operators to assess equipment health, detect abnormal temperature conditions and insulation degradation, and implement predictive maintenance while extending the service life of existing switchgear. Demand is particularly strong in mature power markets such as North America and Europe, where substantial installed electrical infrastructure requires ongoing modernization and condition monitoring. Manufacturers are also developing increasingly connected monitoring solutions incorporating IoT sensors, cloud-based analytics, digital substations, and AI-enabled predictive maintenance, creating additional opportunities as utilities and industries transition toward smarter and more reliable power infrastructure.

By end user, the utilities segment is expected to account for the largest market share over the forecast period.

Utilities are the primary users of switchgear monitoring systems because these solutions are widely deployed across power transmission and distribution networks, substations, and grid infrastructure. They play a crucial role in continuously assessing switchgear condition, detecting abnormal operating conditions, and identifying potential failures before they result in equipment damage or unplanned outages. The expansion and modernization of electricity infrastructure primarily drives growth in the utilities segment. Developing markets are investing in new transmission lines, substations, and renewable power integration, creating opportunities to deploy monitoring systems alongside new switchgear installations. At the same time, mature power markets are replacing aging switchgear and upgrading existing substations with condition-monitoring and predictive-maintenance technologies to improve grid reliability, safety, and operational efficiency. These replacement and modernization activities create recurring demand for switchgear monitoring systems. Utilities are also facing growing pressure to improve asset utilization, reduce maintenance costs, and minimize service interruptions. This is encouraging the adoption of IoT-enabled sensors, thermal monitoring, partial discharge detection, remote diagnostics, and predictive analytics that enable condition-based maintenance and real-time asset visibility. In addition, the increasing integration of renewable energy, distributed generation, battery storage, and digital substations is creating new requirements for intelligent monitoring systems capable of managing increasingly complex and dynamic power networks.

Europe is likely to be the second-largest region in the Switchgear Monitoring System Market during the forecast period.

Europe is likely to be the second-largest region in the Switchgear Monitoring System Market during the forecast period, supported by ongoing grid modernization, replacement of aging electrical infrastructure, increasing renewable energy integration, and stringent requirements for power-system reliability and electrical safety. Countries such as Germany, the UK, France, Italy, Spain, and the Netherlands are investing in transmission and distribution networks, digital substations, offshore wind projects, and smart-grid infrastructure, creating sustained demand for advanced switchgear monitoring solutions. The region is also witnessing increasing adoption of condition monitoring and predictive maintenance technologies as utilities seek to reduce unplanned outages, extend equipment operating life, and improve asset management. Germany, the UK, and France are particularly important markets due to their extensive power infrastructure and significant investments in renewable energy and grid modernization. The expansion of offshore wind and other renewable power projects across Northern and Western Europe is further increasing the need for reliable monitoring of switchgear used in substations and grid connection infrastructure. In addition, Europe's emphasis on digitalization, grid resilience, remote asset monitoring, and predictive maintenance is encouraging the adoption of IoT-enabled sensors, partial discharge monitoring, thermal monitoring, and advanced analytics across utility and industrial applications.

Top Companies in Switchgear Monitoring System Industry:

The Switchgear Monitoring System Industry include Schneider Electric (France), Siemens (Germany), Eaton (Ireland), GE Vernova (US), ABB (Switzerland), Doble Engineering Company (US), Dynamic Ratings (UK), Rugged Monitoring (Canada), PDS (Switzerland), SENSeOR-WIKA Group (France), Hitachi, Ltd. (Japan), Mitsubishi Electric Corporation (Japan), PT. Tiara Vibrasindo Pratama (Indonesia), Emerson Electric Co. (US), Blue Jay Technology Co. Ltd. (China), IPEC Ltd. (UK), Nuventura (Germany), Megger (UK), OSENSA Innovations (Canada), and Monitra Ltd. (UK). These companies compete through broad condition-monitoring portfolios, advanced sensor technologies, partial discharge and thermal monitoring solutions, real-time equipment diagnostics, remote monitoring platforms, and predictive maintenance capabilities for utility, industrial, renewable energy, and transmission and distribution applications.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=69776366

Switchgear Monitoring System Market - Investment & funding + Merger & Acquisition

Investment Funding Context

The market for switchgear monitoring systems is witnessing increased investments from manufacturers, utilities, and governmental bodies, driven by the need to modernize power transmission and distribution infrastructure. This includes initiatives focused on grid expansion, replacement of aging electrical equipment, digital substations, renewable energy integration, and improved grid reliability. The IEA estimates that global energy investment will reach USD 3.4 trillion in 2026, with electricity-related investment accounting for a growing share of total spending; it also estimates that annual grid investment needs to rise from around USD 400 billion currently by roughly 50% by 2030 to meet projected electricity demand.

Revenue Shift Context

The expansion of power transmission and distribution infrastructure is creating a broader addressable market for switchgear monitoring systems.

- Q4 sales increased 10% and organic sales increased 12%*

- Q4 GAAP EPS of $1.60; Q4 Adjusted EPS* of $1.66*

- Q4 orders +44% organically year-over-year

- Backlog of $23.0 billion increased 43% organically year-over-year

* This earnings release contains non-GAAP financial measures. Definitions and reconciliations of the non-GAAP financial measures can be found in the attached footnotes. Non-GAAP measures should be considered in addition to, and not as replacements for, the most comparable GAAP measures.

CORK, Ireland, Oct. 27, 2026 /PRNewswire/ -- Johnson Controls International plc (NYSE: JCI), a global leader in thermal management, mission-critical building systems, energy efficiency, and decarbonization, is proud to announce fiscal fourth quarter 2026 GAAP earnings per share ("EPS") of $1.60. Adjusted EPS was $1.66.

Q4 sales increased 10% to $7.1 billion and organic sales increased 12%.

For the quarter, GAAP net income from continuing operations attributable to JCI was $967 million and adjusted net income from continuing operations was $1.0 billion. Cash provided by operating activities was $1.3 billion. Free cash flow was $1.1 billion and adjusted free cash flow was $1.1 billion.

"We finished fiscal 2026 with significant momentum, delivering more than 8% organic revenue growth, double-digit adjusted EPS growth and strong free cash flow conversion," said Joakim Weidemanis, Chief Executive Officer of Johnson Controls. "Our strong topline growth, combined with continued productivity and simplification improvements, led to margin expansion across all three segments. That performance reflects the strength of our differentiated technological capabilities, unmatched field presence and proprietary business system, which help us move with speed, win with customers and strengthen performance. With record backlog and sustained customer demand, we enter fiscal 2027 with confidence in our ability to continue creating value for customers and shareholders."

FISCAL Q4 SEGMENT RESULTS

The financial highlights presented in the tables below exclude discontinued operations and are in accordance with GAAP, unless otherwise indicated. All comparisons are to the fourth quarter of fiscal 2025. Orders and backlog metrics included in the release relate to the Company's Solutions and Services based businesses. Orders prior to Q1 2026 exclude certain equipment-only sales for longer cycle projects. Backlog has been restated to include this new category.

A slide presentation to accompany the results can be found in the Investor Relations section of Johnson Controls' website at http://investors.johnsoncontrols.com.

Americas

Sales in the quarter of $4.9 billion increased 14% over the prior year. Organic sales also increased 14% led by continued strength in both Applied HVAC & Controls. Products and Systems sales increased 16% and Services increased 10% organically.

Excluding acquisitions and divestitures and adjusted for foreign currency, orders increased 58% year-over-year and backlog of $17.8 billion increased 54% year-over-year. The increase in orders and backlog was supported by sustained demand for data centers and our differentiated technology and capabilities.

Segment EBIT margin increased 250 bp and adjusted Segment EBITA margin increased 210 bp compared to the prior year. The increases were primarily driven by strong operating leverage on higher revenue and favorable business mix. Adjusted Segment EBITA in both Q4 2026 and Q4 2025 excludes transformation costs.

EMEA (Europe, Middle East, Africa)

Sales in the quarter of $1.3 billion decreased 2% over the prior year. Organic sales grew 3% versus the prior year, with continued pressure in the region due to the conflicts in the Middle East. Products and Systems sales remained flat and Services increased 6% organically.

Excluding acquisitions and divestitures and adjusted for foreign currency, orders increased 12% year-over-year and backlog of $3.1 billion increased 18% year-over-year.

Segment EBIT margin increased 100 bps and adjusted Segment EBITA margin increased 80 bps compared to the prior year. The increases were primarily driven by favorable pricing and productivity improvements, partially offset by the impact of business divestitures. Adjusted Segment EBITA in both Q4 2026 and Q4 2025 excludes transformation costs.

APAC (Asia Pacific)

Sales in the quarter of $871 million increased 12% versus the prior year. Organic sales increased 13% versus the prior year, led by 15% growth in Product and Systems and continued strength in Applied HVAC.

Excluding acquisitions and divestitures and adjusted for foreign currency, orders increased 11% and backlog of $2.1 billion increased 12% year-over-year.

Segment EBIT margin increased 120 bps and adjusted Segment EBITA margin increased 110 bps compared to the prior year, primarily driven by productivity improvements and higher revenues.

Corporate

Adjusted Corporate expense in both Q4 2026 and Q4 2025 excludes certain transaction/separation costs and transformation costs. In addition, Q4 2025 excludes accelerated depreciation of ERP assets. The decrease year-over-year is primarily due to ongoing cost reduction actions across corporate functions and the timing of certain corporate expenses.

OTHER Q4 ITEMS

- The Company paid dividends of $242 million.

GUIDANCE

The following forward-looking statements are non-GAAP financial measures. These non-GAAP financial measures are derived by excluding certain amounts from the corresponding financial measures determined in accordance with GAAP. The determination of the amounts excluded is a matter of management judgment and depends upon, among other factors, the nature of the underlying expense or income amounts recognized in a given period and the high variability of certain amounts, such as mark-to-market adjustments. Organic revenue growth excludes the effect of acquisitions, divestitures and foreign currency. The Company is unable to present a quantitative reconciliation of the aforementioned forward-looking non-GAAP financial measures to its most directly comparable forward-looking GAAP financial measures because such information is not available, and management cannot reliably predict the necessary components of such GAAP measures without unreasonable effort or expense. The unavailable information could have a significant impact on the Company's fiscal 2027 first quarter and full year GAAP financial results.

The Company initiated fiscal 2027 first quarter continuing operations guidance:

- Organic sales growth of 12% to 14%

- Operating leverage of 30% to 35%

- Adjusted EPS of $1.15 to $1.20

The Company initiated fiscal 2027 full year continuing operations guidance:

- Organic sales growth of 11% to 12%

- Operating leverage of 30%+

- Adjusted EPS of $6.15 to $6.30

- Adjusted free cash flow conversion of ~95%

CONFERENCE CALL & WEBCAST INFO

Johnson Controls will host a conference call to discuss this quarter's results at 8:30 a.m. ET today, which can be accessed via webcast at https://johnson-controls-q4-2026-earnings.open-exchange.net. A slide presentation will accompany the prepared remarks and has been posted on the investor relations section of the Johnson Controls website at https://investors.johnsoncontrols.com/news-and-events/events-and-presentations. A replay will be made available approximately two hours following the conclusion of the conference call.

ABOUT JOHNSON CONTROLS

Johnson Controls, a global leader in thermal management, mission-critical building systems, energy efficiency, and decarbonization, helps customers use energy more productively, reduce carbon emissions, and operate with the precision and resilience required in rapidly expanding industries such as data centers, healthcare, pharmaceuticals, advanced manufacturing, and higher education.

For more than 140 years, Johnson Controls has delivered performance where it really matters. Backed by advanced technology, lifecycle services and an industry-leading field organization, we elevate customer performance, turn goals into real-world results and help move society forward.

Visit johnsoncontrols.com for more information and follow @Johnson Controls on social platforms.

JOHNSON CONTROLS CONTACTS:

JOHNSON CONTROLS INTERNATIONAL PLC CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Johnson Controls International plc (the "Company") has made statements in this document that are forward-looking and therefore are subject to risks and uncertainties. All statements in this document other than statements of historical fact are, or could be, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In this document, statements regarding the Company's future financial position, sales, costs, earnings, cash flows, other measures of results of operations, synergies and integration opportunities, capital expenditures, debt levels and market outlook are forward-looking statements. Words such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "should," "forecast," "project" or "plan" and terms of similar meaning are also generally intended to identify forward-looking statements. However, the absence of these words does not mean that a statement is not forward-looking.

From AI-powered manufacturing and next-generation control to cybersecurity and digital engineering, Rockwell showcases technologies designed to help manufacturers build the future of industrial operations

MILWAUKEE, Oct. 27, 2026 /PRNewswire/ -- Rockwell Automation, Inc. (NYSE: ROK), the world's largest company dedicated to industrial automation and digital transformation, today announced an expanded product showcase for Automation Fair® 2026. Across the plant floor and enterprise, Rockwell's latest innovations help manufacturers unlock greater productivity, simplify operations and strengthen resilience in an increasingly complex industrial environment. Together, these technologies demonstrate how AI, automation and digital transformation are reshaping the future of industrial operations.

At Automation Fair 2026, attendees will get an exclusive look at new technologies designed to help manufacturers modernize production, accelerate decision-making and scale innovation with greater confidence. The innovations span Rockwell's automation and software portfolio showcasing practical applications that address some of the industry's most pressing operational challenges.

"Production systems today are balancing growth, workforce challenges, cybersecurity threats and the need to adapt faster than ever before," said Matheus Bulho, senior vice president, software & control, Rockwell Automation. "At Automation Fair 2026, we're bringing together hardware, software and industrial intelligence in new ways, giving customers the tools to move faster, adapt with confidence and create more resilient and autonomous operations."

Among the list of record-breaking innovative new technologies being showcased are:

- LogixEdge⢠Controller, enhancing the power of Logix with new form factors and seamless integration of IT and OT workloads that further amplify Logix's powerful multidiscipline control and information capabilities, including AI workloads that enable autonomous control

- CompactLogix® 5390 Controller, delivering enhanced performance and security with greater scalability for modern production system environments.

- PointMax⢠I/O, a next-generation I/O platform designed to simplify deployment and support high-performance machine applications.

- Armor⢠PowerFlex® 330 Integrated Drive Motor, combining motor and drive functionality in a compact solution to reduce complexity and accelerate installation.

- EtherNet/IP⢠In-cabinet Solution, helping manufacturers simplify what it takes to construct, wire, deploy and manage industrial control systems more efficiently.

- FactoryTalk® Optix⢠Version 1.9 and new OptixPanel⢠Pro and PanelView⢠Pro graphic terminals, providing expanded visualization capabilities across larger distributed systems, enhanced security and a modern operator experience.

- FactoryTalk® Conductorâ¢, enabling organizations to orchestrate industrial intelligence and agentic engineering across design, operations and maintenance for their entire operations.

- FactoryTalk® AssetIQâ¢, FactoryTalk® Design Workbench⢠and FactoryTalk® ResilientEdge⢠software, helping customers simplify enterprise OT asset management, streamline engineering and improve resilience of edge deployments.

- New AI innovations for the Plex Smart Manufacturing Platform⢠and AI-powered Quality Management capabilities, bringing practical artificial intelligence to everyday manufacturing workflows.

- Expanded cybersecurity offerings, including SecureOT⢠Platform Managed Services, OT Cybersecurity Assessment Suite, and capabilities designed to support OEMs in building more secure machines from the start

In addition to product announcements, attendees will have the opportunity to experience live demonstrations, engage with Rockwell Automation experts and partners and explore the innovations driving greater productivity, flexibility and resilience across manufacturing.

Registration is now open. Join thousands of industrial professionals at Automation Fair 2026 and be among the first to experience Rockwell's latest innovations in action. Register today at automationfair.com.

About Rockwell Automation

Rockwell Automation, Inc. (NYSE: ROK), is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 26,000 problem solvers dedicated to our customers in more than 100 countries. To learn more about how we are bringing the Connected Enterprise® to life across industrial enterprises, visit www.rockwellautomation.com.

SOURCE Rockwell Automation, Inc.

Share this article

CLEVELAND, Oct. 27, 2026 /PRNewswire/ -- The Sherwin-Williams Company (NYSE: SHW) announced its financial results for the third quarter ended September 30, 2026. All comparisons are to the third quarter of the prior year, unless otherwise noted.

SUMMARY

- Consolidated Net sales increased 7.9% to $6.86 billion in the quarter

- Net sales from stores in the Paint Stores Group open more than twelve calendar months increased 3.9% in the quarter

- Diluted net income per share increased 0.9% to $3.38 per share in the quarter compared to $3.35 per share in the third quarter of 2025

- Adjusted diluted net income per share increased 1.1% to $3.63 per share in the quarter compared to $3.59 per share in the third quarter of 2025

- Net income decreased 1.5% in the quarter to $821.0 million, or 12.0% of Net sales

- Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) in the quarter increased 3.4% to $1.39 billion, or 20.3% of Net sales

- Adjusted EBITDA in the quarter increased 3.3% to $1.40 billion, or 20.5% of Net sales

- Revising full year 2026 diluted net income per share guidance in the range of $10.92 to $11.22 per share, including Valspar acquisition-related amortization expense of $0.82 per share and severance and other restructuring expenses of $0.11 per share

- Narrowing full year 2026 adjusted diluted net income per share guidance in the range of $11.85 to $12.15 per share

CEO REMARKS

"Sherwin-Williams third quarter performance demonstrated the resilience of our Company and the strength of our strategy in a challenging demand environment. Despite muted underlying market volumes, we continued to win new customers, increase share-of-wallet and deliver sales growth across all three reportable segments, at or above our guidance, supported by the differentiated value and productivity our solutions deliver to customers. At the same time, we took disciplined pricing and cost actions to address inflationary pressures, thoughtfully timed with our customers in mind," said Chair, President and Chief Executive Officer, Heidi G. Petz. "Gross margin was primarily impacted in the quarter by higher raw material and supply chain related costs and by mix, including dilution from Suvinil and higher growth in lower margin reportable segments. Excluding the dilutive impact of the Suvinil acquisition, our year-to-date gross margin is flat compared to the prior year. SG&A as a percent of sales decreased in the quarter, as we continue to identify and implement efficiencies throughout our Company. Adjusted EBITDA and adjusted diluted earnings per share both grew over last year's third quarter levels. We returned $749.0 million to shareholders in the quarter through dividends and share repurchases. Our team remains focused on serving our customers and controlling what we can control to continue top and bottom-line growth."

Consolidated Net sales increased primarily due to higher Net sales in all reportable segments, inclusive of the October 2025 acquisition of Suvinil, and selling price increases, which impacted Net sales by a mid-single digit percentage.

Income before income taxes increased slightly due to an increase in Net sales, partially offset by higher raw material and supply chain related costs, incremental selling, general and administrative (SG&A) expenses associated with Suvinil and higher costs in the Administrative function related to additional interest expense attributable to an increase in debt.

Diluted net income per share included a charge of $0.21 and $0.20 per share for Valspar acquisition-related amortization expense in the third quarter of 2026 and 2025, respectively. Diluted net income per share also included a charge of $0.04 per share related to severance and other restructuring expenses in both the third quarter of 2026 and 2025.

Net sales in PSG increased primarily due to selling price increases, which impacted Net sales by a mid-single digit percentage, as well as low-single digit percentage sales volume growth. Net sales increased in all professional customer end markets, led by a double digit percentage increase in protective and marine, a high-single digit percentage increase in commercial and a mid-single digit percentage increase in residential repaint. Segment profit increased primarily due to higher Net sales, partially offset by higher raw material and supply chain related costs and increased costs to support higher sales, including investments in additional sales reps and stores.

Net sales in CBG increased primarily as a result of the acquisition of Suvinil, favorable foreign currency translation and a positive shift in mix, partially offset by soft demand in North America. Segment profit decreased primarily due to higher raw material and supply chain costs, incremental SG&A expenses associated with the Suvinil acquisition and unfavorable foreign currency transaction gains and losses, partially offset by higher Net sales. Adjusted segment profit decreased for these same reasons.

Valspar acquisition-related amortization expense reduced Segment profit as a percent of Net sales by 170 and 200 basis points in the third quarter of 2026 and 2025, respectively. Severance and other restructuring expenses reduced Segment profit as a percent of Net sales by 100 and 90 basis points in the third quarter of 2026 and 2025, respectively.

Net sales in PCG increased primarily due to selling price increases, which impacted Net sales by a mid-single digit percentage, and low-single digit percentage sales volume growth. Net sales increased in all businesses, led by General Industrial, Packaging and Coil, which each increased by a double digit percentage, and Industrial Wood and Automotive Refinish, which each increased by a low-single digit percentage. Segment profit increased primarily due to higher Net sales, partially offset by higher raw material and supply chain related costs and an increase in employee-related costs to support higher sales. Adjusted segment profit increased for these same reasons, including a slight decrease in the expenses associated with targeted restructuring actions in the third quarter of 2026.

Valspar acquisition-related amortization expense reduced Segment profit as a percent of Net sales by 260 and 290 basis points in the third quarter of 2026 and 2025, respectively. Severance and other restructuring expenses reduced Segment profit as a percent of Net sales by 20 and 30 basis points in the third quarter of 2026 and 2025, respectively.

LIQUIDITY AND CASH FLOW

The Company generated $2.59 billion in Net operating cash and returned cash of $2.98 billion to our shareholders in the form of dividends and repurchases of 7.1 million shares of its common stock during the first nine months of 2026. At September 30, 2026, the Company had remaining authorization to purchase 22.5 million shares of its common stock through open market purchases.

2026 GUIDANCE

"Customer sentiment and the leading indicators we track point to muted demand over the remainder of the year and into 2027. As we navigate this environment, our focus remains clear: win in the marketplace, serve our customers, offset inflation, reduce costs and continue to deliver profitable growth and shareholder value," said Ms. Petz.

"Against this backdrop, we expect fourth quarter 2026 consolidated Net sales to increase by a mid-single digit percentage compared to the fourth quarter of 2025, resulting in us maintaining our full year 2026 sales guidance where consolidated Net sales are expected to be up a mid to high-single digit percentage compared to full year 2025. Diluted net income per share is expected to be in the range of $10.92 to $11.22 per share, including acquisition-related amortization expense of $0.82 per share and severance and other restructuring expenses of $0.11 per share, compared to $10.26 per share in 2025. Full year 2026 adjusted diluted net income per share is expected to be in the range of $11.85 to $12.15 per share compared to $11.43 per share in 2025. We remain highly confident in our ability to deliver through current conditions while building an even stronger Sherwin-Williams for the future."

CONFERENCE CALL INFORMATION

The Company will host a conference call to discuss its financial results for the third quarter, and its outlook for the fourth quarter and full year 2026, at 10:00 a.m. EDT on Tuesday, October 27, 2026. Heidi G. Petz, Sherwin-Williams' Chair, President and Chief Executive Officer, along with other senior executives, will participate on the call.

The conference call will be webcast simultaneously in listen only mode. To listen to the webcast on the Sherwin-Williams website, click on https://investors.sherwin-williams.com/financials/quarterly-results/, then click on the webcast icon following the reference to the Q3 webcast. An archived replay of the webcast will be available at https://investors.sherwin-williams.com/financials/quarterly-results/ beginning approximately two hours after the call ends.

ABOUT THE SHERWIN-WILLIAMS COMPANY

Founded in 1866, The Sherwin-Williams Company is a global leader in the manufacture, development, distribution, and sale of paint, coatings and related products to professional, industrial, commercial and retail customers. The Company manufactures products under well-known brands such as Sherwin-Williams®, Valspar®, HGTV HOME® by Sherwin-Williams, Dutch Boy®, Krylon®, Minwax®, Thompson's® WaterSeal®, Cabot®, Suvinil® and many more. With global headquarters in Cleveland, Ohio, Sherwin-Williams® branded products are sold exclusively through a chain of more than 5,400 Company-operated stores and branches, while the Company's other brands are sold through leading mass merchandisers, home centers, independent paint dealers, hardware stores, automotive retailers and industrial distributors.

LONDON, Oct. 27, 2026 /PRNewswire/ -- Brightstar Lottery PLC (NYSE: BRSL) ("Brightstar") announced today that the Illinois Lottery has launched Brightstar's patented Cash Pop⢠draw-based game. The Cash Pop game features hourly drawings with $1, $2, $5, and $10 price points.

"Introducing Brightstar's Cash Pop game to the Illinois Lottery's current portfolio offers new and exciting ways to play," said Harold Mays, Illinois Lottery Director. "We've seen the success this game has had with many of our lottery peers and look forward to it being in our draw-based lineup."

"Brightstar is excited to partner with the innovative Illinois Lottery to expand the reach of our proprietary Cash Pop game while engaging a new audience of players," said Scott Gunn, Brightstar Chief Operating Officer North America. "We are pleased to play a role supporting the Illinois Lottery's responsible growth and funding for its K-12 public education programs."

The Cash Pop game gives players the ability to strategize their wager and create their own personalized experience every time they play, which has proven to be highly engaging among players where it is offered.

The Illinois Lottery is operated by Allwyn Illinois LLC.

About Brightstar Lottery PLC

Brightstar Lottery PLC (NYSE: BRSL) is a global leader in lottery focused on innovation and forward-thinking strategies and solutions, building on our renowned expertise in delivering secure technology and producing reliable, comprehensive solutions for our customers. As a premier pure play global lottery company, our best-in-class lottery operations, retail and digital solutions, and award-winning lottery games enable our customers to achieve their goals, entertain players and distribute meaningful benefits to communities. Brightstar has a well-established local presence and is a trusted partner to governments and regulators around the world, creating value by adhering to the highest standards of service, integrity, and responsibility. Brightstar serves nearly 90 lottery customers and their players on six continents. It is the primary technology provider to 26 of the 46 lottery jurisdictions in the U.S. and eight of the world's 10 largest lotteries with central systems. Brightstar has approximately 6,000 employees. For more information, please visit www.brightstarlottery.com or follow along on LinkedIn.

Cautionary Statement Regarding Forward-Looking Statements

This news release may contain forward-looking statements (including within the meaning of the Private Securities Litigation Reform Act of 1995) concerning Brightstar Lottery PLC and its consolidated subsidiaries (the "Company") and other matters. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, products and services, customer relationships, results of operations, or financial condition, or otherwise, based on current beliefs of the management of the Company as well as assumptions made by, and information currently available to, such management. Forward-looking statements may be accompanied by words such as "aim," "anticipate," "believe," "plan," "could," "would," "should," "shall," "continue," "estimate," "expect," "forecast," "future," "guidance," "intend," "may," "will," "possible," "potential," "predict," "project" or the negative or other variations of them. These forward-looking statements speak only as of the date on which such statements are made and are subject to various risks and uncertainties, many of which are outside the Company's control. Should one or more of these risks or uncertainties materialize, or should any of the underlying assumptions prove incorrect, actual results may differ materially from those predicted in the forward-looking statements and from past results, performance, or achievements. Therefore, you should not place undue reliance on such statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include (but are not limited to) macroeconomic, regulatory and political uncertainty, including as a result of new or increased tariffs, trade wars, and other restrictions on trade between or among countries in which the Company operates, and related changes in discretionary consumer spending and behavior, fluctuations in foreign currency exchange rates, and the other factors and risks described in the Company's annual report on Form 20-F for the financial year ended December 31, 2025 and other documents filed or furnished from time to time with the SEC, which are available on the SEC's website at www.sec.gov and on the investor relations section of the Company's website at www.brightstarlottery.com. Except as required under applicable law, the Company does not assume any obligation to update these forward-looking statements. You should carefully consider these factors and other risks and uncertainties that may affect the Company's business. All forward-looking statements contained in this news release are qualified in their entirety by this cautionary statement. All subsequent written or oral forward-looking statements attributable to the Company, or persons acting on its behalf, are expressly qualified in their entirety by this cautionary statement.

Contact:

Mike DeAngelis, Corporate Communications, +1 (401) 392-1000, [email protected]

Matteo Selva, Italian media inquiries, +39 366 6803635

James Hurley, Investor Relations, +1 (401) 392-7190

© 2026 Brightstar Lottery PLC

The trademarks and/or service marks used herein are either trademarks or registered trademarks of Brightstar Lottery PLC, its affiliates or its licensors.

SOURCE Brightstar Lottery PLC

Share this article